



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 Jan 2018 (#2)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

- Updated Appendix Policy Eliminates Clinical Trial-Related Materials for NIH/AHRQ/NIOSH Applications Submitted to Due Dates on or After January 25, 2018 ([NOT-OD-18-126](#))

1. African Association for Health Professions Education and Research (Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: ([RFA-TW-18-001](#))

Type: R25

Application Due Date: March 28, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet Africa's biomedical, behavioral and clinical research needs by supporting the establishment of an African Association for Health Professions Education and Research (the "Association"). The Association will serve as a leadership and convening organization to network institutions across Africa in order to jointly develop, disseminate, and share best practices, innovations, curricula, and policy and to engage in joint activities that will increase the quantity, quality and retention of African health professionals to address the crisis in HIV/AIDS and its' comorbidities on the continent. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on outreach to broad communities and multiple stakeholders. Among its outreach activities, the Association may sponsor courses for skills development, research experiences, mentoring activities, and curriculum development, as appropriate to its mission.

The applicant may focus on one or more of these areas, it is not necessary to propose activities in all areas.

- **Courses for Skills Development:** For example, workshops and advanced courses (face to face or online) in a specific discipline or research area; clinical procedures for research, research management, or specialized research techniques that are of general importance but where expertise may not be widely distributed; library and database resource skills; data analysis; evaluation of medical apps and devices; implementation science training, including practical skills in working with governments to advise on and implement policy; and many other topics.
- **Research Experiences:** For example, offering opportunities to encourage inter-institutional and/or inter-professional joint research experiences; coordinating the exchange of students and faculty between institutions; stimulating innovation through challenges and hack-a-thons.
- **Mentoring Activities:** For example, support for working groups focused on best practices in career development skills; workshops, online resources, and the creation of peer to peer communities of practice in Mentorship and Leadership; and other activities.
- **Curriculum or Methods Development:** For example, convening working groups from multiple institutions focused on evaluating, developing, and/or implementing new instructional approaches that are scientifically rigorous, conducting joint educational experiments, developing or evaluating new methodologies or computer-based educational tools, and sharing best practices in issues of common concern, such as promoting decentralization of health professional education and improving retention of professionals in the geographic areas with the most need.
- **Outreach:** The Association will be expected to reach out to the African community of health professional educators and researchers. It must provide an annual symposium for networking, and for presentation and sharing of evidence-based educational best practices and research outcomes. Other outreach activities may include, for example: facilitating exchanges among institutions; collaboration with professional associations and Health Training Institutions to track health professions graduates; providing a means for coordination and rapid dissemination of best practices and innovation; encouraging and helping institutions ensure that training curricula and methods meet internationally agreed-upon scientific standards (including regarding HIV/AIDS); providing a forum to implement joint activities; and providing training opportunities of general interest that may be of otherwise limited availability to the membership. The Association may also serve as a common instrument for Outreach to multiple stakeholders, for example: Ministries of Health, Education and Finance; other non-African institutions and organizations with similar goals; international funding agencies, and communities, among others. The Association is encouraged to host a website that will enhance visibility, coordination, and outreach efforts and serve as a vehicle for information sharing and communication.

Research education programs may complement ongoing research training and education occurring at the applicant institution, but the proposed educational experiences must be distinct from those training and education programs currently receiving U.S. government support.

Budget: Issuing IC and partner components intend to commit an estimated total of \$750,000 in FY18 for one award. Applicants may request up to \$750,000 per year total costs. Up to five years.

2. Understanding Immunopathogenesis of Tuberculosis in HIV-1 Infected and Exposed Children (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-17-039](#)

Type: R01

Application Due Date: March 14, 2018. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support research that will identify changes in immune mechanisms and markers because of Mycobacterium tuberculosis (M.tb) exposure, infection or disease in pediatric populations exposed to or infected with HIV-1.

Budget: NIAID intends to commit \$3.8 million in FY 2019 to fund 3 to 5 awards. Application budgets for studies proposing to use non-human primates are capped at \$850,000 (direct costs) per year. Application budgets for all other applications are capped at \$500,000 (direct costs) per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

3. Understanding and Modifying Temporal Dynamics of Coordinated Neural Activity (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-554\)](#)
[\(PAR-18-555\)](#)

Type: R21
R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: A rich body of evidence suggests that optimal cognitive, affective, and social processes are associated with highly coordinated neural activity. These findings suggest that oscillatory rhythms, their co-modulation across frequency bands, spike-phase correlations, spike population dynamics, and other patterns might be useful drivers of therapeutic development for treatment of cognitive, social, or affective symptoms in neuropsychiatric disorders. This funding opportunity supports projects that test whether modifying electrophysiological patterns during behavior can improve cognitive, affective, or social processing. Applications must use experimental designs that incorporate active manipulations to address at least one, and ideally more, of the following topics: (1) in animals or humans, determine which parameters of neural coordination, when manipulated in isolation, improve particular aspects of cognitive, affective, or social processing; (2) in animals or humans, determine how particular abnormalities at the genomic, molecular, or cellular levels affect the systems-level coordination of electrophysiological patterns during behavior; (3) determine whether in vivo, systems-level electrophysiological changes in behaving animals predict analogous electrophysiological and cognitive improvements in healthy persons or clinical populations; and (4) use biologically-realistic computational models that include systems-level aspects to understand the function and mechanisms by which oscillatory and other electrophysiological patterns unfold across the brain to impact cognitive, affective, or social processing. The R21 grant mechanism, encouraging shorter, higher-risk applications, whereas its companion funding opportunity seeks R01 grant applications.

Budget: R21- The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

4. Cancer Prevention and Control Clinical Trials Grant Program (Clinical Trial Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-559\)](#)

Type: R01

Application Due Date: March 15, 2018; then [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications for support of investigator-initiated clinical trials that have the potential to reduce the burden of cancer through improvements in early detection, prevention, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. This FOA does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients. The proposed investigator-initiated projects should be related to the programmatic interests of the NCI Division of Cancer Prevention and/or the NCI Division of Cancer Control and Population Sciences as based on their scientific missions.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trials Required)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-560\)](#)

Type: R01

Application Due Date: March 15, 2018; then [Standard dates](#) Aids Dates May 7, 2018; [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to seek research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis (DCTD). Applicants are strongly encouraged to consult the NCI DCTD website at <https://dctd.cancer.gov/> to learn more about the various program goals, research priorities, and strategies developed to fight cancer. Applications submitted to this FOA must include studies that meet the National Institutes of Health (NIH) definition of a clinical trial (see NOT-OD-15-015 for details) and provide specific clinical trial information as described in this FOA. Applications that propose phase III clinical trials in any area of cancer research are not sought by and will not be supported through this FOA.

Budget: Application budgets are limited to less than \$500,000 in direct costs per year. The maximum project period is 5 years.

6. Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (Clinical Trials Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAS-18-557\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.

Budget: NIH intends to fund an estimate of 4-6 awards, corresponding to a total of \$3 million per year, for fiscal year 2018 to 2022.

Application budgets must not exceed \$500,000 per year in direct cost. The scope of the proposed project should determine the project period. The award project period may not exceed 5 years.

7. Hearing Health Care for Adults: Improving Access and Affordability (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-382\)](#)

Type: R21

[\(PA-18-438\)](#)

R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This FOA encourages exploratory and developmental research applications for research on hearing health care in adults in support of improving access and affordability. Further research is needed to strengthen the evidence base with a goal of delivering better health care outcomes in adults.

Budget: R21 = Direct Costs maximum of \$275,000 over two years with no more than \$200,000 direct costs in either year. The maximum project period is 2 years. R01=Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

8. International Research Collaboration on Drug Abuse and Addiction Research (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-568\)](#)

Type: R01

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDA's international scientific priority areas (<http://www.drugabuse.gov/international/research-priorities>). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

9. Underactive Bladder and Detrusor Activity in Aging (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PA-18-570\)](#)

Type: R01

[\(PA-18-571\)](#)

R03

[\(PA-18-572\)](#)

R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that propose basic, clinical, or translational research on underactive bladder (UAB) and detrusor underactivity (DU) and its consequences in aging and in older persons. Applications should focus on the 1) biology, etiology and pathophysiology of DU or UAB in animal models and/or older adults; 2) translation of basic/clinical research into clinical practice and health decision making; 3) diagnosis, prevention, management and clinical outcomes of UAB in older adults; and/or 4) epidemiology and risk factors for the development of DU/UAB with advancing age. Research supported by this initiative should enhance knowledge of DU/UAB and its consequences in older adults and provide evidence-based guidance in the diagnosis, evaluation, and treatment of DU/UAB in older persons.

Budget: R01 = Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R03 = The combined budget for direct costs for the two-year project period may not exceed \$100,000. No more than \$50,000 in direct costs may be requested in any single year. The maximum project period is 2 years. R21 = The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. The maximum project period is 2 years.

10. Cutting-Edge Basic Research Awards (CEBRA) (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-437\)](#)

Type: R21

Application Due Date: August 20, 2018; December 20, 2018; August 20, 2019; December 20, 2019; August 20, 2020; and December 18, 2020 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). It supports high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio. The proposed research should: (1) test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking; and/or (2) develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research.

Budget: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$150,000 in direct costs may be requested in any single year. The maximum project period is 2 years.

11. Emotional Function in Normal Aging and/or MCI and AD/ADRD

Letter of Intent: 30 days prior to the application due date

Hyperlink: [\(PAR-18-581\)](#)
[\(PAR-18-582\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) invites applications that expand on foundational research demonstrating generally improved emotional function and emotion regulation with aging, to further clarify the trajectories of change in emotion processing and linked neurobiological factors in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer's disease (AD), and Alzheimer's disease-related dementias (ADRD). The goal is three-fold: to advance understanding of (1) normative maturational shifts in emotional processes, (2) how dysfunction in the integrative neural-behavioral mechanisms of emotional function might manifest in MCI and the early stages of AD/ADRD, and/or (3) how such dysfunction might account for any of the neuropsychiatric symptoms observed in AD/ADRD. Such studies may identify novel targets for interventions or prevention efforts, or provide clues to intervention strategies that might be applied to normalize emotion dysregulation or strengthen emotional resilience at different life stages in normal aging or disease stages in MCI and AD/ADRD. This FOA invites Stage 0 (basic research) or Stage 1 (intervention development/modification) clinical trials, in line with the NIH Stage Model.

Budget: R01 = Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 = The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. The maximum project period is 2 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).